A-Synuclein

Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease

A-Synuclein, Biomarkers, Pre-PD /

Parkinson’s disease (PD) is a progressive neurodegenerative disorder, which is characterised by degeneration of distinct neuronal populations, including dopaminergic neurons of the substantia nigra. Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid. We used liquid chromatographymass spectrometry (LC-MS) to analyse 274 samples […]

Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease Read More »

Prefrontal network dysfunctions in rapid eye movement sleep behavior disorder

A-Synuclein, iRBD, Pre-PD /

We found abnormal ECN and normal DMN as a possible hallmark of cognitive dysfunctions in early α-synucleinopathies. We replicated abnormalities in BGN and SMN corresponding to subclinical movement disorder of RBD. RsfcMRI may provide an early biomarker of both cognitive and motor network dysfunctions of α-synucleinopathies. CLICK TO REVIEW

Prefrontal network dysfunctions in rapid eye movement sleep behavior disorder Read More »

The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer’s Disease and Parkinson’s Disease

A-Synuclein, Biomarkers, Pre-PD /

This review aims to provide an insight into the current literature concerning salivary biomarkers used in the diagnosis of AD and PD. The most commonly studied salivary biomarkers in AD are β-amyloid1-42/1-40 and TAU protein, as well as α-synuclein and protein deglycase (DJ-1) in PD. Studies continue to be conducted on this subject and researchers

The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer’s Disease and Parkinson’s Disease Read More »

CSF Biomarker Flags Parkinson’s Pathology Years Before Symptoms Appear

A-Synuclein, Biomarkers, iRBD, Pre-PD, Vagal Nerve /

Real-time quaking-induced conversion (RT-QuIC), a test for pathological misfolded protein, detected alpha-synuclein in the cerebrospinal fluid (CSF) of patients with isolated rapid-eye-movement (REM) sleep behavior disorder (IRBD), years before clinical symptoms of Parkinson’s disease or dementia with Lewy bodies emerged. In these patients, RT-QuIC detected misfolded alpha-synuclein in CSF with both sensitivity and specificity of

CSF Biomarker Flags Parkinson’s Pathology Years Before Symptoms Appear Read More »

Cross-seeding of alpha-synuclein aggregation by amyloid fibrils of food proteins

A-Synuclein, ENS, Vagal Nerve /

In this work, we investigated the ability of amyloid fibrils derived from two food proteins to heterologously seed the aggregation of the PD-related aSyn protein. While β-lactoglobulin amyloid fibril seeds were not able to induce aSyn aggregation, we identified a fibril surface–mediated nucleation mechanism for the seeding of aSyn aggregation by hen egg white lysozyme

Cross-seeding of alpha-synuclein aggregation by amyloid fibrils of food proteins Read More »

The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson’s disease

A-Synuclein /

 Interestingly, we found that TCE not only induced LRRK2 kinase activity in the brain, but produced a significant dopaminergic lesion in the nigrostriatal tract, elevated oxidative stress, and caused endolysosomal dysfunction and α-synuclein accumulation. Together, these data suggest that TCE-induced LRRK2 kinase activity contributed to the selective toxicity of dopaminergic neurons. We conclude that gene-environment interactions

The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson’s disease Read More »

The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer’s Disease and Parkinson’s Disease

A-Synuclein, Biomarkers, iRBD, Pre-PD /

This review aims to provide an insight into the current literature concerning salivary biomarkers used in the diagnosis of AD and PD. The most commonly studied salivary biomarkers in AD are β-amyloid1-42/1-40 and TAU protein, as well as α-synuclein and protein deglycase (DJ-1) in PD. Studies continue to be conducted on this subject and researchers

The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer’s Disease and Parkinson’s Disease Read More »

Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models

A-Synuclein, Pre-PD /

Tat-βsyndegron decreased α-synuclein aggregates and microglial activation in an α-synuclein preformed fibril model of spreading synucleinopathy in transgenic mice overexpressing human A53T α-synuclein. Moreover, Tat-βsyn-degron reduced α-synuclein levels and significantly decreased the parkinsonian toxin-induced neuronal damage and motor impairment in a mouse toxicity model of PD. These results show the promising efficacy of Tat-βsyn-degron in

Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models Read More »

Short-chain fatty acids in the context of Parkinson’s disease

A-Synuclein, Butyrate, Short Chain Fatty Acids /

Taken together, there is strong evidence that the gastrointestinal microbiome is altered in PD and this is similarly true for the composition of the intestinal metabolome. SCFAs are increasingly studied intestinal metabolites that have shown great potential to influence disease processes in neuroinflammatory disorders. Their role for neurodegenerative movement disorders such as PD is still

Short-chain fatty acids in the context of Parkinson’s disease Read More »

Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study

A-Synuclein, Biomarkers, Dementia - Lewy Bodies, iRBD, Pre-PD /

In patients with IRBD, RT-QuIC detects misfolded α-synuclein in the CSF with both sensitivity and specificity of 90%, and α-synuclein positivity was associated with increased risk of subsequent diagnosis of Parkinson’s disease or dementia with Lewy bodies. Detection of α-synuclein in the CSF represents a potential prodromal marker of Parkinson’s disease and dementia with Lewy bodies. If

Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study Read More »